Marizomib

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameMarizomib
Drug Alias Name玛利佐米MarizomibumSalinosporamide ANPI-0052
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionProteasome inhibitorsApoptosis stimulants
TargetsProteasome
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBrain Stem NeoplasmsBrain Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTriphase Accelerator Corp
China Registration ClassN/A

Develop Information

Active CompaniesCelgene Corp
Inactive CompaniesDana-Farber Cancer InstituteBristol Myers Squibb SrlcompanyNational Cancer Institute
Active IndicationsGlioblastomaGlioma
Inactive IndicationsCarcinoma, Non-Small-Cell LungBrain Stem NeoplasmsBrain Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksKEGG